.png){kind=icon}
返回
Breaking a Vicious Cycle
.png){kind=icon}
PRE
AI
DOI：10.1126/scitranslmed.3005950.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Despite prodigious advances in tumor biology research, few tumor-biomarker tests have been adopted as standard clinical practice. This lack of reliable tests stems from a vicious cycle of undervaluation, resulting from inconsistent regulatory standards and reimbursement, as well as insufficient investment in research and development, scrutiny of biomarker publications by journals, and evidence of analytical validity and clinical utility. We of er recommendations designed to serve as a roadmap to break this vicious cycle and call for a national dialogue, as changes in regulation, reimbursement, investment, peer review, and guidelines development require the participation of all stakeholders.
Keyword:
TUMOR-MARKERS
AMERICAN SOCIETY
CLINICAL UTILITY
CANCER
BIOMARKERS
INDUSTRY
TRIALS
DESIGN
ASSAY
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.6
论文数:
5.0K
被引数:
6.5W
机构
引用论文
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - An economic analysis based on prognostic and predictive validation studies.png)
CANCER
CANCERIF5.1
PREAI
分享收藏Design of Tumor Biomarker-Monitoring Trials: A Proposal by the European Group on Tumor MarkersCLINICAL CHEMISTRY
OAAI
CLINICAL CHEMISTRYIF6.3
OAAI分享收藏分享收藏CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized TrialsCONSORT 2010声明: 报告平行组随机试验的更新指南OAAI
OAAI分享收藏
查看更多内容